Ionis Pharmaceuticals, Inc. is on track for back-to-back drug launches after announcing positive Phase III data on its ligand-conjugated anti-sense (LICA) medicine donidalorsen as a prophylactic treatment for hereditary angioedema (HAE), which Ionis could submit for US Food and Drug Administration approval soon after it submits olezarsen for familial chylomicronemia syndrome (FCS).
Ionis Poised To Build Out Commercial Portfolio With Donidalorsen Success
A Phase III study testing the ligand-conjugated anti-sense medicine in hereditary angioedema read out positively, but the drug would join a competitive market if approved.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.